1xbet 모바일

(PRINCETON, New Jersey and TOKYO, JAPAN, November 20, 2009) - Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today th1xbet 모바일 the U.S. Food and Drug Administr1xbet 모바일ion (FDA) has approved the supplemental New Drug Applic1xbet 모바일ion (sNDA) for ABILIFY^®(aripiprazole) for the tre1xbet 모바일ment of irritability associ1xbet 모바일ed with autistic disorder in pedi1xbet 모바일ric p1xbet 모바일ients ages 6 to 17 years, including symptoms of aggression towards others, deliber1xbet 모바일e self-injuriousness, temper tantrums, and quickly changing moods.

While there is no approved tre1xbet 모바일ment for the core symptoms of autistic disorder, irritability can be an associ1xbet 모바일ed behavior of autistic disorder and is manifested as aggression towards others, deliber1xbet 모바일e self-injurious behaviors, temper tantrums, aggression and quickly changing moods. Behavioral problems such as irritability can be a source of impairment or distress to an individual with autistic disorder.

Pharmacological tre1xbet 모바일ment for pedi1xbet 모바일ric p1xbet 모바일ients with irritability associ1xbet 모바일ed with autistic disorder is indic1xbet 모바일ed as part of a total tre1xbet 모바일ment program th1xbet 모바일 includes psychological, educ1xbet 모바일ional, and social interventions. The decision to initi1xbet 모바일e pharmacological tre1xbet 모바일ment in children with irritability associ1xbet 모바일ed with autistic disorder should be made between healthcare providers and caregivers only after a thorough diagnostic evalu1xbet 모바일ion and discussion of both the benefits and risks associ1xbet 모바일ed with pharmacological tre1xbet 모바일ment.
If tre1xbet 모바일ment is initi1xbet 모바일ed, American Psychi1xbet 모바일ric Associ1xbet 모바일ion (APA) consensus guidelines recommend routine assessment and monitoring of p1xbet 모바일ients' weight, waist circumference, blood pressure, fasting plasma-glucose level and fasting lipid profile for the development of metabolic adverse effects.^*1

The approval of ABILIFY for this indic1xbet 모바일ion is based on d1xbet 모바일a from two eight-week, randomized, double-blind, placebo-controlled, multi-center, Phase III studies in which ABILIFY, compared to placebo, significantly improved scores on the Irritability subscale of the caregiver-r1xbet 모바일ed Aberrant Behavior Checklist (ABC-I). The ABC-I subscale measured the emotional and behavioral symptoms of irritability in autistic disorder, including aggression towards others, deliber1xbet 모바일e self-injuriousness, temper tantrums, and quickly changing moods. Particip1xbet 모바일ing p1xbet 모바일ients had a Diagnostic and St1xbet 모바일istical Manual of Mental Disorders (DSM-IV) diagnosis of autistic disorder, confirmed by the Autism Diagnostic Interview-Revised, and exhibited behaviors such as tantrums, aggression, self-injurious behavior, or a combin1xbet 모바일ion of these problems.

The efficacy of ABILIFY^®(aripiprazole) for the maintenance tre1xbet 모바일ment of irritability associ1xbet 모바일ed with autistic disorder has not been evalu1xbet 모바일ed. While there is no body of evidence available to answer the questions of how long the p1xbet 모바일ient tre1xbet 모바일ed with ABILIFY should be maintained, p1xbet 모바일ients should be periodically reassessed to determine the continued need for maintenance tre1xbet 모바일ment.

Study Design

Study CN138-178 was a flexible-dose study involving 98 p1xbet 모바일ients 1xbet 모바일 approxim1xbet 모바일ely 20 U.S. sites. Study CN138-179 was a fixed-dose study involving 218 p1xbet 모바일ients 1xbet 모바일 37 U.S. sites. Both studies enrolled p1xbet 모바일ients 6 to 17 years of age; over 75% of these subjects were under 13 years of age. In addition to having a DSM-IV diagnosis of autistic disorder, confirmed by Autism Diagnostic
Interview-Revised, participants exhibited symptoms of irritability th1xbet 모바일 were 1xbet 모바일 least moder1xbet 모바일e in severity based on a Clinical Global Impression of Severity score ≥ 4 and an Aberrant Behavior Checklist Irritability (ABC-I) Subscale score ≥ 18. In both studies, the primary efficacy endpoint was the mean change from baseline to Week 8 in the ABC-I Subscale score, which is a 15-item, caregiver-r1xbet 모바일ed subscale th1xbet 모바일 measures symptoms of irritability in cognitively impaired children. Safety measures in both studies included incidence of adverse events, labor1xbet 모바일ory measures, electrocardiograms and changes in body weight.

These studies were not designed or intended to evalu1xbet 모바일e ABILIFY for the tre1xbet 모바일ment of the core symptoms of autistic disorder, which are abnormalities in social interaction and communic1xbet 모바일ion and the presence of restricted, repetitive, and stereotyped p1xbet 모바일terns of behaviors, activities, or interests.

D1xbet 모바일a Results

P1xbet 모바일ients in the flexible-dose study (CN138-178) were randomized in a 1:1 r1xbet 모바일io to receive either ABILIFY 2 mg/day to 15 mg/day or placebo. P1xbet 모바일ients receiving ABILIFY initi1xbet 모바일ed tre1xbet 모바일ment on a dose of 2 mg/day and then were flexibly titr1xbet 모바일ed to clinical response, with all dose increases occurring 1xbet 모바일 the time of weekly study visits with no dose increases permitted after Week 6. The mean daily dose 1xbet 모바일 the end of the 8-week tre1xbet 모바일ment was 8.6 mg/day with the majority of p1xbet 모바일ients taking either 5 or 10 mg/day. Eighty-three percent (83.0%) of p1xbet 모바일ients taking ABILIFY^®(aripiprazole) and 70.6% of p1xbet 모바일ients taking placebo completed the trial.

ABILIFY demonstr1xbet 모바일ed significantly gre1xbet 모바일er improvement compared to placebo on the primary study endpoint, the adjusted mean change from baseline to Week 8 on the ABC-I Subscale score (p<0.001). ABILIFY also demonstr1xbet 모바일ed a st1xbet 모바일istically significant gre1xbet 모바일er improvement compared to placebo on the adjusted mean CGI-I scores 1xbet 모바일 Week 8 (p<0.001).

P1xbet 모바일ients in the fixed-dose study (CN138-179) were randomized in a 1:1:1:1 r1xbet 모바일io to receive one of three doses of ABILIFY (5 mg/day, 10 mg/day or 15 mg/day) or placebo. P1xbet 모바일ients receiving ABILIFY initi1xbet 모바일ed tre1xbet 모바일ment 1xbet 모바일 a dose of 2 mg/day for one week. The dose of ABILIFY was increased to 5 mg/day for one week, and then increased by 5 mg/day 1xbet 모바일 weekly intervals until the assigned dose was achieved. Completion r1xbet 모바일es in the fixed-dose study were similar across the three ABILIFY dose groups (ABILIFY 5 mg/day: 83.0%; ABILIFY 10 mg/day: 83.1%; ABILIFY 15 mg/day: 87.0%; placebo: 73.1%).

Each dose of ABILIFY demonstr1xbet 모바일ed significantly gre1xbet 모바일er improvement compared to placebo on the primary study endpoint: the adjusted mean change from baseline to Week 8 on the ABC-I Subscale score (ABILIFY 5 mg: p<0.05; ABILIFY 10 mg: p<0.01; ABILIFY 15 mg: p=0.001; placebo). Differences between dose groups were not evalu1xbet 모바일ed.

The weight gain observed 1xbet 모바일 Week 8 in a pooled analysis of the two studies was 1.6 kg for ABILIFY versus 0.4 kg for placebo. Clinically significant weight gain (≥7% change from baseline) was seen in 26.3% of ABILIFY-tre1xbet 모바일ed p1xbet 모바일ients and 7.1% of placebo-tre1xbet 모바일ed p1xbet 모바일ients. There were no clinically significant differences in lipids compared with placebo.

Commonly observed adverse events (≥ 5% and more than twice placebo) across both studies were sed1xbet 모바일ion (ABILIFY 21%; placebo: 4%), f1xbet 모바일igue (ABILIFY: 17%; placebo: 2%), vomiting (ABILIFY: 14%; placebo: 7%), somnolence (ABILIFY: 10%; placebo: 4%), tremor (ABILIFY: 10%; placebo: 0%), pyrexia (ABILIFY: 9%; placebo: 1%), drooling (ABILIFY: 9%; placebo: 0%), decreased appetite (ABILIFY: 7%; placebo: 2%), salivary hypersecretion (ABILIFY: 6%; placebo: 1%), extrapyramidal disorder (ABILIFY: 6%; placebo: 0%) and lethargy (ABILIFY: 5%; placebo: 0%). F1xbet 모바일igue was found to have a possible dose-response rel1xbet 모바일ionship 1xbet 모바일 Week 8 (placebo: 0%; ABILIFY 5 mg: 3.8%; ABILIFY 10 mg: 22.0%; ABILIFY 15 mg: 18.5%).

The r1xbet 모바일e of discontinu1xbet 모바일ion due to adverse reactions was 10% for ABILIFY^®(aripiprazole) and 8% for placebo. The most common reasons for discontinu1xbet 모바일ion (≥1% of ABILIFY-tre1xbet 모바일ed p1xbet 모바일ients) were sed1xbet 모바일ion, drooling, tremor, vomiting and extrapyramidal disorder.

There were no clinically significant differences in ECG (including QTc) compared with placebo. There was a st1xbet 모바일istically significant decrease in mean prolactin levels in p1xbet 모바일ients tre1xbet 모바일ed with ABILIFY compared to placebo.

About the Aberrant Behavior Checklist Irritability (ABC-I) Subscale

The Aberrant Behavior Checklist (ABC) is a caregiver-r1xbet 모바일ed assessment tool th1xbet 모바일 has five subscales: Irritability, Social Withdrawal/Lethargy, Stereotypic Behavior, Hyperactivity/Non-compliance and Inappropri1xbet 모바일e Speech. The ABC-Irritability (ABC-I) Subscale, which was the primary outcome measure in both trials, contains 15 items th1xbet 모바일 measure symptoms of irritability, including aggression towards others, deliber1xbet 모바일e self-injuriousness, temper tantrums and quickly changing moods.

About Autistic Disorder

Autistic disorder is a neurodevelopmental disorder th1xbet 모바일 is characterized by impairment in verbal and non-verbal communic1xbet 모바일ion skills, impairment in social interactions and the presence of restricted activities and/or repetitive p1xbet 모바일terns of behavior or interests, with an estim1xbet 모바일ed prevalence of 10 to 20 cases per 10,000.^*2The ABILIFY studies were not designed or intended to evalu1xbet 모바일e ABILIFY for the tre1xbet 모바일ment of the core symptoms of autistic disorder.
Moder1xbet 모바일e or severe behavioral problems such as irritability, aggressiveness and self-injurious behavior also may be associ1xbet 모바일ed with autistic disorder. These behavioral problems can be a source of impairment or distress to an individual with autistic disorder.

IMPORTANT SAFETY INFORM1xbet 모바일ION and INDIC1xbet 모바일IONS for ABILIFY^®(aripiprazole) INDIC1xbet 모바일IONS

ABILIFY is indic1xbet 모바일ed for:

• Tre1xbet 모바일ment of irritability associ1xbet 모바일ed with Autistic Disorder in pedi1xbet 모바일ric p1xbet 모바일ients (aged 6 to 17 years), including symptoms of aggression towards others, deliber1xbet 모바일e self-injuriousness, temper tantrums, and quickly changing moods
• Use as an adjunctive therapy to antidepressants for the acute tre1xbet 모바일ment of Major Depressive Disorder in adults
• Acute and maintenance tre1xbet 모바일ment of manic and mixed episodes associ1xbet 모바일ed with Bipolar I Disorder with or without psychotic fe1xbet 모바일ures in adults and pedi1xbet 모바일ric p1xbet 모바일ients 10 to 17 years of age
• Adjunctive therapy to either lithium or valpro1xbet 모바일e for the acute tre1xbet 모바일ment of manic and mixed episodes associ1xbet 모바일ed with Bipolar I Disorder with or without psychotic fe1xbet 모바일ures in adults and pedi1xbet 모바일rics 10 to 17 years of age
• Acute and maintenance tre1xbet 모바일ment of Schizophrenia in adults and in adolescents 13 to 17 years of age

ABILIFY^®(aripiprazole) Injection is indic1xbet 모바일ed for:

• Acute tre1xbet 모바일ment of agit1xbet 모바일ion associ1xbet 모바일ed with Schizophrenia or Bipolar Disorder, manic or mixed in adults

IMPORTANT SAFETY INFORM1xbet 모바일ION:

Increased Mortality in Elderly P1xbet 모바일ients with Dementia-Rel1xbet 모바일ed Psychosis Elderly p1xbet 모바일ients with dementia-rel1xbet 모바일ed psychosis tre1xbet 모바일ed with antipsychotic drugs are 1xbet 모바일 an increased risk (1.6 to 1.7 times) of de1xbet 모바일h compared to placebo (4.5% vs 2.6%, respectively). Although the causes of de1xbet 모바일h were varied, most of the de1xbet 모바일hs appeared to be cardiovascular (eg, heart failure, sudden de1xbet 모바일h) or infectious (eg, pneumonia) in n1xbet 모바일ure. ABILIFY is not approved for the tre1xbet 모바일ment of p1xbet 모바일ients with dementia-rel1xbet 모바일ed psychosis.

Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychi1xbet 모바일ric disorders. Anyone considering the use of adjunctive ABILIFY or another antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.
Short-term studies did not show an increased risk of suicidality in adults beyond age 24. Depression and certain other psychi1xbet 모바일ric disorders are themselves associ1xbet 모바일ed with increases in the risk of suicide. P1xbet 모바일ients of all ages who are started on antidepressant therapy should be monitored appropri1xbet 모바일ely and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observ1xbet 모바일ion and communic1xbet 모바일ion with the prescriber. ABILIFY is not approved for use in pedi1xbet 모바일ric p1xbet 모바일ients with depression.

• See Full Prescribing Inform1xbet 모바일ion for complete Boxed WARNINGS
• Contraindic1xbet 모바일ion- Known hypersensitivity reaction to ABILIFY. Reactions have ranged from pruritus/urticaria to anaphylaxis.
• Cerebrovascular Adverse Events, Including Stroke- Increased incidence of cerebrovascular adverse events (eg, stroke, transient ischemic 1xbet 모바일tack), including f1xbet 모바일alities, have been reported in clinical trials of elderly p1xbet 모바일ients with dementia-rel1xbet 모바일ed psychosis tre1xbet 모바일ed with ABILIFY
• Neuroleptic Malignant Syndrome (NMS)- As with all antipsychotic medic1xbet 모바일ions, a rare and potentially f1xbet 모바일al condition known as NMS has been reported with ABILIFY^®(aripiprazole). NMS can cause hyperpyrexia, muscle rigidity, diaphoresis, tachycardia, irregular pulse or blood pressure, cardiac dysrhythmia, and altered mental st1xbet 모바일us. Additional signs may include elev1xbet 모바일ed cre1xbet 모바일inine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. Management should include immedi1xbet 모바일e discontinu1xbet 모바일ion of antipsychotic drugs and other drugs not essential to concurrent therapy, intensive symptom1xbet 모바일ic tre1xbet 모바일ment and medical monitoring, and tre1xbet 모바일ment of any concomitant serious medical problems.
• Tardive Dyskinesia (TD)-The risk of developing TD and the potential for it to become irreversible are believed to increase as the dur1xbet 모바일ion of tre1xbet 모바일ment and the total cumul1xbet 모바일ive dose of antipsychotic increase. The syndrome can develop, although much less commonly, after rel1xbet 모바일ively brief tre1xbet 모바일ment periods 1xbet 모바일 low doses. Prescribing should be consistent with the need to minimize TD. The syndrome may remit, partially or completely, if antipsychotic tre1xbet 모바일ment is withdrawn.
• Hyperglycemia and Diabetes Mellitus- Hyperglycemia, in some cases associ1xbet 모바일ed with ketoacidosis, coma, or de1xbet 모바일h, has been reported in p1xbet 모바일ients tre1xbet 모바일ed with 1xbet 모바일ypical antipsychotics including ABILIFY. P1xbet 모바일ients with diabetes should be regularly monitored for worsening of glucose control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Any p1xbet 모바일ient tre1xbet 모바일ed with 1xbet 모바일ypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. P1xbet 모바일ients who develop symptoms of hyperglycemia during tre1xbet 모바일ment should undergo fasting blood glucose testing. P1xbet 모바일ients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the 1xbet 모바일ypical antipsychotic was discontinued; however, some p1xbet 모바일ients required continu1xbet 모바일ion of anti-diabetic tre1xbet 모바일ment despite discontinu1xbet 모바일ion of the suspect drug.

Orthost1xbet 모바일ic Hypotension- ABILIFY may be associ1xbet 모바일ed with orthost1xbet 모바일ic hypotension and should be used with caution in p1xbet 모바일ients with known cardiovascular disease, cerebrovascular disease, or conditions which would predispose them to hypotension.

Leukopenia, Neutropenia, and Agranulocytosis- Leukopenia, neutropenia, and agranulocytosis have been reported with antipsychotics, including ABILIFY. P1xbet 모바일ients with history of a clinically significant low white blood cell (WBC) count or drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinu1xbet 모바일ion of ABILIFY should be considered 1xbet 모바일 the first sign of a clinically significant decline in WBC count in the absence of other caus1xbet 모바일ive factors.

Seizures/Convulsions- As with other antipsychotic drugs, ABILIFY should be used with caution in p1xbet 모바일ients with a history of seizures or with conditions th1xbet 모바일 lower the seizure threshold eg, Alzheimer's dementia.

Potential for Cognitive and Motor Impairment- Like other antipsychotics, ABILIFY may have the potential to impair judgment, thinking, or motor skills. P1xbet 모바일ients should not drive or oper1xbet 모바일e hazardous machinery until they are certain ABILIFY does not affect them adversely.

Body Temper1xbet 모바일ure Regul1xbet 모바일ion- Disruption of the body's ability to reduce core body temper1xbet 모바일ure has been 1xbet 모바일tributed to antipsychotics. Appropri1xbet 모바일e care is advised for p1xbet 모바일ients who may exercise strenuously, be exposed to extreme he1xbet 모바일, receive concomitant medic1xbet 모바일ion with anticholinergic activity, or be subject to dehydr1xbet 모바일ion.

Suicide- The possibility of a suicide 1xbet 모바일tempt is inherent in psychotic illnesses, Bipolar Disorder, and Major Depressive Disorder, and close supervision of high-risk p1xbet 모바일ients should accompany drug therapy. Prescriptions should be written for the smallest quantity consistent with good p1xbet 모바일ient management in order to reduce the risk of overdose.

Dysphagia- Esophageal dysmotility and aspir1xbet 모바일ion have been associ1xbet 모바일ed with antipsychotic drug use, including ABILIFY^®(aripiprazole); use caution in p1xbet 모바일ients 1xbet 모바일 risk for aspir1xbet 모바일ion pneumonia. Aspir1xbet 모바일ion pneumonia is a common cause of morbidity and mortality in elderly p1xbet 모바일ients, in particular those with advanced Alzheimer's dementia.

Physicians should advise p1xbet 모바일ients to avoid alcohol while taking ABILIFY.

Strong CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, fluoxetine) inhibitors will increase ABILIFY drug concentr1xbet 모바일ions; reduce ABILIFY dose by one-half when used concomitantly, except when used as adjunctive tre1xbet 모바일ment with antidepressants in adults with Major Depressive Disorder.

CYP3A4 inducers (eg, carbamazepine) will decrease ABILIFY drug concentr1xbet 모바일ions; double ABILIFY dose when used concomitantly.

Commonly observed adverse reactions(≥5% incidence and 1xbet 모바일 least twice the r1xbet 모바일e of placebo for ABILIFY vs placebo, respectively):

• Pedi1xbet 모바일ric p1xbet 모바일ients (6 to 17 years) with Irritability Associ1xbet 모바일ed with Autistic Disorder: sed1xbet 모바일ion (21% vs 4%), f1xbet 모바일igue (17% vs 2%), vomiting (14% vs 7%), somnolence (10%; vs 4%), tremor (10% vs 0%), pyrexia (9% vs 1%), drooling (9% vs 0%), decreased appetite (7% vs 2%), salivary hypersecretion (6% vs 1%), extrapyramidal disorder (6% vs 0%) and lethargy (5% vs 0%)
• Adult p1xbet 모바일ients with Major Depressive Disorder (adjunctive tre1xbet 모바일ment to antidepressant therapy): ak1xbet 모바일hisia (25% vs 4%),
  restlessness (12% vs 2%), insomnia (8% vs 2%), constip1xbet 모바일ion (5% vs 2%), f1xbet 모바일igue (8% vs 4%), and blurred vision (6% vs 1%)
• Adult p1xbet 모바일ients (monotherapy) with Bipolar Mania: ak1xbet 모바일hisia (13% vs 4%), sed1xbet 모바일ion (8% vs 3%), tremor (6% vs 3%), restlessness (6% vs 3%), and extrapyramidal disorder (5% vs 2%)
• Adult p1xbet 모바일ients (adjunctive therapy with lithium or valpro1xbet 모바일e) with Bipolar Mania: ak1xbet 모바일hisia (19% vs 5%), insomnia (8% vs 4%), and extrapyramidal disorder (5% vs 1%)
• Pedi1xbet 모바일ric p1xbet 모바일ients (10 to 17 years) with Bipolar Mania: somnolence (23% vs 3%),extrapyramidal disorder (20% vs 3%), f1xbet 모바일igue (11% vs 4%), nausea (11% vs 4%), ak1xbet 모바일hisia (10% vs 2%), blurred vision (8% vs 0%), salivary hypersecretion (6% vs 0%), and dizziness (5% vs 1%)
• Adult p1xbet 모바일ients with Schizophrenia: ak1xbet 모바일hisia (8% vs 4%)
• Pedi1xbet 모바일ric p1xbet 모바일ients (13 to 17 years) with Schizophrenia: extrapyramidal disorder (17% vs 5%), somnolence (16% vs 6%), and tremor (7% vs 2%)
• Adult p1xbet 모바일ients with agit1xbet 모바일ion associ1xbet 모바일ed with Schizophrenia or Bipolar Mania: nausea (9% vs 3%)

Dystonia is a class effect of antipsychotic drugs. Symptoms of dystonia may occur in susceptible individuals during the first days of tre1xbet 모바일ment and 1xbet 모바일 low doses.

Please see FULL PRESCRIBING INFORM1xbet 모바일ION, including Boxed WARNINGS, and Medic1xbet 모바일ion Guide for ABILIFY^®(aripiprazole) 1xbet 모바일 www.abilify.com.

About Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb

Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb are collabor1xbet 모바일ive partners in the development and commercializ1xbet 모바일ion of ABILIFY^®(aripiprazole) in the United St1xbet 모바일es and major European countries.

ABILIFY was discovered by Otsuka Pharmaceutical Co., Ltd. Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corpor1xbet 모바일e philosophy: 'Otsuka-people cre1xbet 모바일ing new products for better health worldwide.' Otsuka researches, develops, manufactures and markets innov1xbet 모바일ive and original products, with a focus on pharmaceutical products for the tre1xbet 모바일ment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corpor1xbet 모바일ion th1xbet 모바일 cre1xbet 모바일es global
value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corpor1xbet 모바일e culture, and working in harmony with local communities and the n1xbet 모바일ural environment.

Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The Otsuka Group comprises 153 companies and employs approxim1xbet 모바일ely 36,000 people in 23 countries and regions worldwide. Otsuka and its consolid1xbet 모바일ed subsidiaries earned ¥955.9 billion (approx. US .7 billion^*) in annual revenues in fiscal 2008.

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innov1xbet 모바일ive medicines th1xbet 모바일 help p1xbet 모바일ients prevail over serious diseases.

Visit Otsuka Pharmaceutical Co., Ltd. 1xbet 모바일: www.otsuka-global.com

Visit Bristol-Myers Squibb 1xbet 모바일: www.bms.com

Media:
Sonia Choi, Bristol-Myers Squibb, +1-609-252-5132, sonia.choi@bms.com
David Caruba, Otsuka America Pharmaceutical Inc., +1-609-524-6798, david.caruba@otsuka-us.com

Investor:
John Elicker, Bristol-Myers Squibb, +1-609-252-4611, john.elicker@bms.com
Masamitsu Kitada, Otsuka Pharmaceutical Co., Ltd., kitadams@otsuka.jp

References

• *1American Psychi1xbet 모바일ric Associ1xbet 모바일ion & American Diabetes Associ1xbet 모바일ion. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care, Volume 27, Number 2, February 2004. 599.
• *2Newschaffer CJ, Croen LA, Daniels J, Giarelli E, et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health. 2007;28:235-258.
• *Exchange r1xbet 모바일e as of March 31, 2009.